Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights

Affiliations

¹ School of Medicine, University of Nevada, Las Vegas, NV.
² Arizona Liver Health, Phoenix, AZ.
³ Henry Ford Health System, Detroit, MI.
⁴ Division of Digestive and Liver Diseases, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.

Comment

Nabil Noureddin et al. Hepatology. 2020 Dec.

. 2020 Dec;72(6):2228-2230.

doi: 10.1002/hep.31498. Epub 2020 Dec 3.

¹ School of Medicine, University of Nevada, Las Vegas, NV.
² Arizona Liver Health, Phoenix, AZ.
³ Henry Ford Health System, Detroit, MI.
⁴ Division of Digestive and Liver Diseases, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.

No abstract available

Comment on

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA. Newsome PN, et al. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. doi: 10.1016/S2468-1253(19)30383-8. Epub 2020 Feb 3. Lancet Gastroenterol Hepatol. 2020. PMID: 32027858 Free PMC article. Clinical Trial.

1. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123-133.
1. Noureddin M, Sanyal AJ. Pathogenesis of NASH: the impact of multiple pathways. Curr Hepatol Rep 2018;17:350-360.
1. Noureddin N, Schattenberg JM, Alkhouri N, Noureddin M. Noninvasive testing using magnetic resonance imaging techniques as outcomes in nonalcoholic steatohepatitis clinical trials: how full is the glass? Hepatol Commun 2020;4:141-144.
1. Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan W-K, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:362-373.
1. Boursier J, Guillaume M, Leroy V, Irles M, Roux M, Lannes A, et al. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol 2019;71:389-396.